In February 2018, YL Biologics had announced completion of the global phase III study of their biosimilar Etanercept
from Latest News https://ift.tt/2Ue7vaL
Tuesday, 26 March 2019
Lupin, YL Biologics get nod to market rheumatoid arthritis drug in Japan
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment